Bnp Paribas Financial Markets Rotates From Mega-Cap AI To Spread Trades

The biggest dollar add is Oracle, up 123.5% with about a $727.1M increase, turning it into a core enterprise AI and database bet rather than a sidecar. That sits alongside a 33.3% lift in Alphabet’s GOOG line (roughly +$559.2M), effectively re-underwriting Alphabet as an AI infrastructure and cloud utility even as they modestly trim the GOOGL line.

Semiconductor and tools exposure is getting an aggressive upgrade. Broadcom is up 10.9%, Texas Instruments 13.0%, Applied Materials slightly higher, Intel nudged up, and ASML almost doubled (+94.5%, about +$326.9M) — that cluster says they’re betting on the capex and memory side of the AI buildout, not just GPUs.

The most striking pivot is into macro and thematic ETFs. They add roughly $583.5M to the SPDR S&P Biotech ETF (XBI), blow out positions in iShares MSCI South Korea (EWY, +5863.9%, about +$671.4M), and ramp both LQD and HYG by more than 5,000% and 82.6% in shares respectively (about +$668.6M and +$233.8M). Layer on a 58.3% boost to the iShares Semiconductor ETF (SOXX), plus sizable increases in IGV and EMB, and the pattern is clear: they want liquid, lever‑like exposure to biotech, semis, Korea and credit spreads.

On the defensive growth side, they materially increase Walmart (+61.4%), Johnson & Johnson (+32.9%), Eli Lilly (+16.5%), UnitedHealth (+11.1%) and Procter & Gamble (+27.2%). These moves round out a barbell where one side is high-beta AI and biotech, and the other is staple cash-flow compounding and health care.

The sell list reads like a who’s who of the last leg of the AI and consumer melt-up. Apple is the largest trim by far, with shares cut 38.8% and an estimated -$1.87B in exposure despite still sitting on a 37.3% gain versus cost; that’s classic de-risking, not a thesis abandonment. Meta sees a 28.8% reduction (about -$802.8M), while Nvidia — the poster child of the AI cycle — is eased back by 6.3% (roughly -$381.0M) even as they sit on a 133.4% gain.

On the consumer side, they are clearly less comfortable at current valuations. Amazon is trimmed 17.4% (about -$667.2M), Netflix is cut by 27.7%, and Costco is almost halved (-49.8%, roughly -$547.5M). For a book that has compounded strongly over three and five years, this looks like disciplined profit-taking where multiples have outrun their comfort zone.

Legacy tech and cyclicals are being used as funding sources too. Cisco is cut by 29.8% (around -$432.7M), AMD by 30.9% (about -$389.8M) despite a 224.6% gain, and Micron and Analog Devices both see mid- to high-teens reductions. Exxon Mobil is down 30.7% (roughly -$284.4M) while gold (GLD) is trimmed 15.0%, signaling less enthusiasm for commodity and outright hedge exposure now that they can express caution through credit and rate-sensitive ETFs instead.

Technology is still the spine of this book at 51.65%, but that’s down from 55.18%, and the sector is internally rotating. Capital is moving out of the mega-cap platforms (Apple, Meta, some Microsoft, some Amazon) and into diversified semis and software infrastructure (Broadcom, ASML, Texas Instruments, Oracle, Alphabet’s GOOG, Intel, TSM and SOXX). It’s a pivot from single-name headline risk toward plumbing — foundry, memory, analog, EDA-adjacent and enterprise software.

The biggest percentage change by bucket is the jump in unclassified holdings from 13.8% to 18.79%. That basket is dominated by ETFs: XBI, SPY, IWM, EWY, LQD, SOXX, EMB, IGV, HYG, GLD and IVV. Read together, these are levers on biotech beta, US large and small caps, Korea, semis, emerging markets debt, software and both investment-grade and high-yield credit — a macro and factor book layered on top of their stock picking.

Outside tech and ETFs, Health Care edges up from 4.07% to 4.52% as they bulk up UNH, LLY, JNJ and modestly hold ABBV, reinforcing a secular earnings‑defensive tilt. Real-world financials (JPM, BAC, Progressive) net to a stable 5.11%, while Energy slips from 1.5% to 1.03% on the Exxon trim. The so‑called “Real Estate” bucket in the screener is actually payments and consulting — Visa, Mastercard, Accenture — and it rises from 2.43% to 3.13%, underscoring a quiet bet on global transaction volumes and IT spending rather than property.

Taken together, the moves say Bnp Paribas Financial Markets still believes in AI and growth, but on their terms. They’re moving away from simple mega-cap momentum and towards infrastructure, second-derivative plays and liquid macro expressions that can be sized up or down quickly.

The barbell is clear: semi tools, AI infrastructure, biotech and Korea on one side; quality consumer, health care, payments and a thick sleeve of investment-grade and high-yield credit on the other. That positioning should benefit if AI capex and biotech risk appetite remain robust, equity dispersion stays high and credit spreads don’t blow out.

At the same time, by trimming Exxon, gold and some of the richest consumer and platform names, they’re implicitly saying the easy money in the broad AI/consumer melt-up and commodity hedge trade is behind us. Going forward, expect this investor to lean even more on ETFs and liquid thematics to express macro and factor views, while keeping a tighter, infrastructure‑heavy roster of single-name tech bets at the core.